Research Article
RSC Medicinal Chemistry
Conflicts of interest
pulmonary fibrosis, Expert Opin. Invest. Drugs, 2014, 23,
893–910.
There is no conflict of interest to declare.
6 G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford and G.
Oster, Incidence and prevalence of idiopathic pulmonary
fibrosis, Am. J. Respir. Crit. Care Med., 2006, 174, 810–816.
7 L. Nalysnyk, J. Cid-Ruzafa, P. Rotella and D. Esser, Incidence
and prevalence of idiopathic pulmonary fibrosis: review of
the literature, Eur. Respir. J., 2012, 21, 355–361.
8 A. L. Olson, J. J. Swigris, D. C. Lezotte, J. M. Norris, C. G.
Wilson and K. K. Brown, Mortality from pulmonary fibrosis
increased in the united states from 1992 to 2003, Am. J.
Respir. Crit. Care Med., 2007, 176, 277–284.
Acknowledgements
We would like to thank Dr. Jiancun Zhang for the help on the
preparation of this manuscript. We also appreciate the
support from Guangdong Innovative and Entrepreneurial
Research Team Program (2016ZT06Y616), Dong Guan
Innovative Research Team Program (201460720200028),
National Major Scientific and Technological Special Project
for “Significant New Drugs Development” during the
Thirteenth Five-Year Plan Period (2018ZX09201002-001 &
2017ZX09201006) and Key Science & Technology Brainstorm
Project of Dongguan (2019622102009). We would like to
com/) for the expert linguistic services provided.
9 J. M. Samet, D. Coultas and G. Raghu, Idiopathic pulmonary
fibrosis: tracking the true occurrence is challenging, Eur.
Respir. J., 2015, 46, 604–606.
10 G. Raghu, B. Rochwerg, Y. Zhang, C. A. Cuello Garcia, A.
Azuma, J. Behr, J. L. Brozek, H. R. Collard, W. Cunningham,
S. Homma, T. Johkoh, F. J. Martinez, J. Myers, S. L. Protzko,
L. Richeldi, D. Rind, M. Selman, A. Theodore, A. U. Wells, H.
Hoogsteden and H. J. Schünemann, An official ATS/ERS/JRS/
ALAT clinical practice guideline: treatment of idiopathic
pulmonary fibrosis, an update of the 2011 clinical practice
guideline, Am. J. Respir. Crit. Care Med., 2015, 192, e3–e19.
11 P. J. Wolters, H. R. Collard and K. D. Jones, Pathogenesis of
idiopathic pulmonary fibrosis, Annu. Rev. Pathol.: Mech. Dis.,
2014, 9, 157–179.
12 A. D. Sario, E. Bendia, G. S. Baroni, F. Ridolfi, A. Casini, E.
Ceni, S. Saccnomanno, M. Marzioni, L. Trozzi, P. Sterpetti, S.
Taffetani and A. Benedetti, Effect of pirfenidone on rat
hepatic stellate cell proliferation and collagen production,
J. Hepatol., 2002, 37, 584–591.
Notes and references
1 J. Hutchinson, A. Fogarty, R. Hubbard and T. McKeever,
Global incidence and mortality of idiopathic pulmonary
fibrosis:
a systematic review, Eur. Respir. J., 2015, 46,
795–806.
2 G. Raghu, H. R. Collard, J. J. Egan, F. J. Martinez, J. Behr,
K. K. Brown, T. V. Colby, J.-F. Cordier, K. R. Flaherty, J. A.
Lasky, D. A. Lynch, J. H. Ryu, J. J. Swigris, A. U. Wells, J.
Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina,
D. M. Hansell, T. Johkoh, D. S. Kim, T. E. King, Jr., Y.
Kondoh, J. Myers, N. L. Müller, A. G. Nicholson, L. Richeldi,
M. Selman, R. F. Dudden, B. S. Griss, S. L. Protzko and H. J.
Schünemann, An official ATS/ERS/JRS/ALAT statement:
idiopathic pulmonary fibrosis: evidence-based guidelines for
diagnosis and management, Am. J. Respir. Crit. Care Med.,
2011, 183, 788–824.
13 Q. Shi, X. Y. Liu, Y. Y. Bai, C. J. Cui, J. Li, S. S. Hu and Y. J.
Wei, In vitro effects of pirfenidone on cardiac fibroblasts:
proliferation, myofibroblast differentiation, migration and
cytokine secretion, PLoS One, 2011, 6(11), e28134.
3 (a) P. Spagnolo, N. Sverzellati, G. Rossi, A. Cavazza, A.
Tzouvelekis, B. Crestani and C. Vancheri, Idiopathic
pulmonary fibrosis: an update, Ann. Med., 2015, 47, 15–27;
(b) M. Selman, V. J. Thannickal, A. Pardo, D. A. Zisman, F. J.
Martinez and J. P. Lynch, 3rd, Idiopathic pulmonary fibrosis:
pathogenesis and therapeutic approaches, Drugs, 2004, 64,
405–430; (c) R. Ziobro, B. Henry, M. J. Edwards, A. B.
Lentsch and E. Gulbins, Ceramide mediates lung fibrosis in
cystic fibrosis, Biochem. Biophys. Res. Commun., 2013, 434,
705–709; (d) M. S. Wilson and T. A. Wynn, Pulmonary
fibrosis: pathogenesis, etiology and regulation, Mucosal
Immunol., 2009, 2, 103–121; (e) Z. Ma, Y. Pan, W. Huang, Y.
Yang, Z. Wang, Q. Li, Y. Zhao, X. Zhang and Z. Shen,
Synthesis and biological evaluation of the pirfenidone
derivatives as antifibrotic agents, Bioorg. Med. Chem. Lett.,
2014, 24, 220–223.
14 S. Nakayama, H. Mukae, N. Sakamoto, T. Kakugawa, S.
Yoshioda, H. Soda, H. Oku, Y. Urata, T. Kondo, H. Kubota,
K. Nagata and S. Kohno, Pirfenidone inhibits the expression
of HSP47 in TGF-β1-stimulated human lung fibroblasts, Life
Sci., 2008, 82, 210–217.
15 N. W. Todd, I. G. Luzina and S. P. Atamas, Molecular and
cellular mechanisms of pulmonary fibrosis, Fibrog. Tissue
Repair, 2012, 5, 11.
16 A. K. Ghosh, S. E. Quaggin and D. E. Vaughan, Molecular
basis of organ fibrosis: potential therapeutic approaches,
Exp. Biol. Med., 2013, 238, 461–481.
17 D. J. Lederer and F. J. Martinez, Idiopathic pulmonary
fibrosis, N. Engl. J. Med., 2018, 378, 19.
18 P. J. Wip, D. B. Rifkin, J. J. Meister and B. Hinz,
Myofibroblast contraction activates latent TGF-β1 from the
extracellular matrix, J. Cell Biol., 2007, 179, 1311–1323.
19 L. Richeldi, H. R. Collard and M. G. Jones, Idiopathic
pulmonary fibrosis, Lancet, 2017, 389, 1941–1952.
20 T. Wohlfahrt, S. Rauber, S. Uebe, M. Luber, A. Soare, A.
Ekici, S. Weber, A. E. Matei, C. W. Chen, C. Maier, E.
Karouzakis, H. P. Kiener, E. Pachera, C. Dees, C. Beyer, C.
4 H. J. Kim, D. Perlman and R. Tomic, Natural history of
idiopathic pulmonary fibrosis, Respir. Med., 2015, 109,
661–670.
5 S. Chakraborty, P. Chopra, S. V. Ambi, S. G. Dastidar and A.
Ray, Emerging therapeutic interventions for idiopathic
1230 | RSC Med. Chem., 2021, 12, 1222–1231
This journal is © The Royal Society of Chemistry 2021